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Abstract 
Recent studies from the Melikian Laboratory demonstrate that KCNK3, a 
potassium channel found in humans, relies on 14-3-3-β for PKC stimulated endocytosis.  
This MQP examined whether or not the dopamine transporter protein (DAT), a related 
membrane protein, also relies on 14-3-3-β for PKC stimulated endocytosis. Data shows 
that 14-3-3-β co-localizes with DAT at the surface of PC12 cells and suggests that 14-3-
3-β is needed for DAT PKC induced endocytosis to occur in SK-N-MC cells. 
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Background 
Anatomy of a Neuron 
 Neurons are the basic building blocks of the nervous system that are responsible 
for transmitting and receiving information. Each component of the neuron plays a crucial 
role in the transmission of information. Most neurons consist of three main parts: (1) a 
dendrite, (2) a cell body, or soma, (3) and an axon as can be seen in Figure 1 in the 
Figures Section (Freeman and Hamilton). 
The dendrites are the tree-like extensions found at the beginning of the neuron 
that are responsible for receiving electro-chemical signals. The cell body, which contains 
the nucleus, integrates incoming signals and generates outgoing signals to the axon. The 
axon passes electro-chemical signals to dendrites of another cell at the terminal button 
regions in a space designated the synapse. When two neuron cells meet at a synapse the 
cell sending an electrical signal is called the pre-synaptic neuron and the cell receiving an 
electrical signal is called the post-synaptic neuron (Freeman and Hamilton). 
Action Potentials 
Neurons conduct electrical signals by using the action potential, which is caused 
by the flow of positively charged ions across the neuronal membrane. In almost all cells, 
including neurons, the extracellular and intracellular fluid contains unequal amounts of 
ions. This uneven distribution of ions is caused by the inherent selectivity of the neuronal 
membrane for certain ions. Specifically the neuronal membrane contains potassium 
channels that are more permeable to potassium ions than sodium channels that are 
permeable to sodium ions. The net result is that there is a slow outward leak of potassium 
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ions that is larger than the inward leak of sodium ions. This means that the membrane has 
a charge on the inside face that is negative relative to the outside. This difference in 
concentration and charge of ions on either side of the membrane gives rise to the 
membrane potential (Freeman and Hamilton).   
 When a stimulus causes the membrane potential to increase, this increase in 
voltage across the membrane induces special sodium ion channels, called voltage-gated 
ion channels, to open. Consequently sodium ions flow into the cell depolarizing the 
intracellular fluid, or allowing the charge of the intracellular fluid to build up positively. 
This causes potassium channels to open which causes potassium to leave the intracellular 
fluid thereby re-polarizing the cell. It is this cycle of depolarization and re-polarization 
that is termed an action potential (Freeman and Hamilton).  
 Action potentials propagate down an axon by what is called a positive feedback 
loop. This occurs when a depolarized region of the axon, or more positively charged area 
of the axon, is able to induce sodium voltage-gated membranes nearby to open up and 
cause sodium ions to flow into the intracellular fluid causing a chain reaction of action 
potentials. The reason why action potentials only propagate down an axon in one 
direction is because sodium voltage-gated membranes have a refractory period when they 
can no longer respond to an increase in membrane potential following activation. 
It is this positive feedback loop that is ultimately responsible for neurotransmission 
(Freeman and Hamilton).   
 Neurotransmission 
Neurotransmission occurs when an electrical impulse called an action potential 
travels along the axon of a pre-synaptic neuron toward the axon terminal. Since the action 
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potential can not cross the synaptic cleft, it causes vesicles to move toward the membrane 
of the axon terminal to fuse with the terminal membrane and enable the vesicle to release 
neurotransmitters into the synaptic cleft by exocytosis. When the neurotransmitters are 
released in the synaptic cleft they are able to bind to receptors on the post-synaptic 
membrane, which is shown in Figure 2. 
Binding of a neurotransmitter to its receptor on the post-synaptic membrane can 
then activate channels in the post-synaptic neuron resulting in a change in the membrane 
potential. This initiates an excitatory or inhibitory post-synaptic potential depending on 
whether it causes the post-synaptic neuron to depolarize or hyperpolarize respectively. If 
depolarization occurs, then an action potential is transmitted down the neuronal pathway 
of the post-synaptic neuron which can go on to induce action potentials in adjacent 
neurons. If hyper-polarization occurs then an excess negative charge is built up in the 
intracellular fluid that decreases the chances of an action potential occurring (Freeman 
and Hamilton).  
Once the action potential is initiated, the neurotransmitter must then be rapidly 
removed from the synaptic cleft, to enable the post-synaptic cell to engage in another 
cycle of signal generation. One of the ways by which neurotransmitters are removed from 
the synaptic cleft is via reuptake by neurotransmitter reuptake proteins embedded in the 
axonal membrane. Thus the mechanisms by which these integral membrane proteins 
traffic to and from the membrane have an in important role in overall neurotransmission. 
Membrane Proteins and Trafficking 
Reuptake transporter proteins are membrane proteins that are embedded in the 
neuron’s axonal lipid bi-layer and thus are classified as integral membrane proteins. The 
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topology of these transporter proteins is shared and they all contain twelve trans-
membrane domains, cytoplasmic amino- and carboxy- terminals, a large second 
extracellular loop with multiple N-linked glycosylation sites, and cytoplasmic 
phosphorylation sites (Yamashita et al.). Since neurotransmitters cannot diffuse through 
the membrane because they are hydrophilic, the transporter protein forms a passage 
through the membrane that allows the polar neurotransmitter to pass through the 
hydrophobic core of the membrane. (Torres et al).  
The amount of reuptake transporter proteins present in the axonal membrane and 
thereby the amount of neurotransmitter that is removed from the synaptic cleft, are 
regulated by a process called endocytosis. One type of endocytosis that provides the 
means for the selective uptake of molecules is called receptor-mediated endocytosis. 
Receptor-mediated endocytosis, which is shown in Figure 3, occurs when a ligand binds 
to a receptor, which is located in an endocytic pit. The endocytic pit forms a vesicle 
around the target receptor protein and buds off to fuse with an endosome. The endosome, 
which is a membrane bound compartment, provides an environment for material to be 
sorted before it is degraded.  
One common type of receptor-mediated endocytosis among membrane proteins is 
clathrin-dependent encodcytosis. Clathrin-dependent endocytosis begins when a ligand 
binds to a specific cell surface receptor protein that is concentrated in a clathrin-coated 
pit. In order for the receptor protein to be bound in a clathrin-coated pit, it must bind to a 
protein called adaptin that is responsible for binding clathrin molecules found on the 
cytosolic side of the membrane (Cooper and Hausman). Once the ligand binds to its 
receptor, which has been coated with clathrin molecules, it starts to bend, forming a 
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vesicle inside the cytoplasm of the cell. The vesicle is eventually excised from the 
membrane by a GTPase protein called dynamin (Praefcke et al).  
Upon excision from the membrane, the vesicle fuses with an early endosome. 
Early endosomes have a lowered pH (5.9-6) which causes the ligand to release from its 
receptor protein. The receptor protein is then either recycled back to membranes in the 
trans-Golgi complex or recycled to the surface by vesicles that bud from the endosome 
and then target the plasma membrane. After the recycling vesicles fuse with the plasma 
membrane, the receptor is returned to the cell surface for further binding and 
activity. When the recycling process has finished, the early endosome then converts to a 
late endosome (Cooper and Hausman).  
The late endosome is formed when the pH drops to 5.0 and it functions to degrade 
many proteins and lipids. Any material that is not digested by the late endosome is then 
digested by the lysosome when the late endosome and lysosome fuse together, creating a 
hybrid organelle (Cooper and Hausman).  
The trafficking of the dopamine transporter protein (DAT) follows a receptor-
mediated endocytosis however its internalization into an endosome does not. Instead of 
relying on the binding of neurotransmitter for internalization to occur, DAT can 
internalize independent of a dopamine association in a manner that relies on three amino 
acids (Leucine 591, Tyrosine 593 and Isoleucine 595) found at its carboxy terminus. 
Thus DAT is constantly being internalized into the cell, trafficking into endosomes, and 
being recycled back to the membrane or degraded.  
Dopamine and the Dopamine Transporter Protein 
Dopamine (DA) is classified as a catecholamine neurotransmitter, which means it 
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acts as both a neurotransmitter and “fight or flight” hormone. Dopamine is found mostly 
in the substantia nigra and ventral tegmental areas of the brain where it is biosynthesized 
first by the hydroxylation of the amino acid L-tyrosine to L-DOPA via the enzyme 
tyrosine 3-monooxygenase and then by the decarboxylation of L-DOPA by aromatic L-
amino acid decarboxylase. It can be further enzymatically processed into the 
neurotransmitters norepinephrine and epinephrine by the enzymes dopamine beta-
hydroxylase and phenylethanolamine N-methyltransferase respectively (Elsworth et al).  
Dopamine has many roles in the brain, which include roles in motor function, 
cognition, and rewarding behaviors. Thus it is implicated in many diseases, such as 
Attention Deficit Hyperactive Disorder, Schizophrenia and Parkinson’s Disease. 
Treatments for these disorders seek to favorably alter dopamine neurotransmission 
(Carlsson et al). 
  Dopamine neurotransmission is regulated by DAT which removes dopamine from 
the synaptic cleft and transmits it back into the pre-synaptic terminal thereby terminating 
the signal of the neurotransmitter (Giros et al). DAT is a sodium and chloride dependent 
transporter protein that is part of a family of transporter proteins, which includes 
transporters for neurotransmitters serotonin (5-HT), norepinephrine (NE), γ-amino 
butyric acid (GABA) and glycine. DAT acts as a symporter that moves dopamine across 
the cell membrane by coupling it to the energetically favorable process of sodium ions 
moving down their concentration and electrical gradient (Melikian, 2004).  
DAT contains 12 transmembrane segments connected by alternating extracellular and 
intracellular loops with the N- and C-termini located in the cytosol as can be seen in 
Figure 4.  
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DAT is a dynamic membrane protein that is recycled from the inside of a neuron 
cell to the membrane of the neuron and internalized from the membrane of the neuron 
back to the inside of the neuron cell under basal conditions. The respective rates of these 
two situations are approximately the same so the amount of DAT present at the 
membrane never really changes. The Melikian Laboratory has shown that specific amino 
acid residues are needed in order for this process to occur. These amino acids are found 
on the carboxy terminus of DAT and are Leucine 591, Tyrosine 593 and Isoleucine 595 
(Boudanova et al). It is thought that these residues bind to an adaptor complex which 
recruits DAT to an endocytic pit where it can become internalized independent of an 
association with dopamine.  
Interestingly DAT has been shown to increase internalization when Protein 
Kinase C (PKC) is activated by a compound that mimics PKC’s natural activator 
diacylglycerol (DAG). Specifically, when a phorbol ester known as PMA (phorbol 12-
myristate 13-acetate) is exposed to cells expressing DAT, PKC becomes activated and 
DAT internalization rates increase while DAT recycling rates decrease, effectively 
lessening the amount of DAT present in the plasma membrane and prolonging dopamine 
neurotransmission (Holton et al). The Melikian laboratory has shown that specific amino 
acid residues within the carboxy terminus of DAT are needed in order for PKC 
accelerated DAT internalization to occur and these residues are Phenylalanine 587, 
Arginine 588, Glutamic Acid 589 and Lysine 590. When these residues are all mutated to 
Alanines, basal DAT internalization rates are significantly enhanced to levels comparable 
to those of wildtype during PKC accelerated DAT endocytosis (Boudanova et al).  
These findings suggest that a braking mechanism likely regulates DAT endocytosis in a 
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manner shown in Figure 5. 
Despite these interesting discoveries much of the DAT endocytosis pathway is 
still presently unknown and many of the molecular players involved in the pathway have 
yet to be characterized. However, one particular molecule that may be involved in the 
pathway and may shed some light on the overall endocytosis process is 14-3-3-β. 
14-3-3 Proteins 
14-3-3 proteins are a family of regulatory molecules that are likely expressed in 
all eukaryotic cells, and that have the ability to bind to signaling proteins such as kinases, 
phosphatases, and trans-membrane receptors. Due to this ability, 14-3-3 proteins play 
important roles in regulatory processes such as signal transduction, apoptosis and cell 
cycle control (Aitken).  
The name 14-3-3 is derived from the combination of the protein’s fraction number 
on DEAE-cellulose chromatography and its migration position in starch–gel 
electrophoresis (Fu et al). 14-3-3 proteins are part of a highly homologous family of 
proteins encoded by separate genes. Currently there are seven known isoforms of 14-3-3 
designated β, ε, γ, η, σ, τ, and ζ. Xray crystallography of 14-3-3ζ and 14-3-3τ have 
revealed that the protein exists as a dimer and that each monomer consists of 9 α-helices 
organized in an antiparallel arrangement, which can be seen in Figure 6 (Liu et al).  
The molecule has a cup-like shape and consists of an inner concave surface that is 
highly conserved and an outer variable surface. Inside the inner concave surface is an 
amphipathic groove on each monomer that has the conserved amino acid residues Lysine 
49, Arginine 56, and Arginine 127, which mediate the interaction of each monomer with 
a phosphorylated serine. The 14-3-3 dimer can simultaneously bind two ligands, which 
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may allow 14-3-3 to operate as a scaffold protein to induce protein-protein associations. 
(Braselmann et al). 
A recent study shows that a 14-3-3 protein has a role in Na/K-ATPase 
internalization via phosphorylation of the cytoplasmic domain of Na/K-ATPase and 
subsequent binding of 14-3-3 followed by clathrin-mediated endocytosis (Efendiev et 
al.). When Na/K-ATPase is phosphorylated via a G protein-coupled receptor signal, the 
serine 18 residue of the Na/K-ATPase cytoplasmic alpha subunit is phosphorylated. 
When 14-3-3 protein is present clathrin-mediated endocytosis proceeds and when 14-3-3 
protein is absent clathrin-mediated endocytosis does not proceed, suggesting a necessary 
association between 14-3-3 protein and Na/K-ATPase in order for internalization to 
occur. Additionally recent studies from the Melikian laboratory demonstrate that 
KCNK3, a potassium channel found in humans, shares an endocytic sequence with DAT 
and relies on 14-3-3-β for PKC stimulated internalization.  
These findings have prompted the question of whether or not 14-3-3-β has a role 
in DAT PKC mediated internalization. Seeing that Na/K-ATPase and KCNK3 are related 
membrane transporter proteins and seeing that 14-3-3 proteins act within many cell 
signaling pathways it is not unreasonable to think that PKC stimulated DAT endocytosis 
may rely on 14-3-3-β. 
In this study 14-3-3-β was selectively knocked down by small hairpin RNA 
(shRNA) to examine whether or not it acts within the DAT PKC activated internalization 
pathway. Additionally DAT and 14-3-3-β were tagged with alexa 594, a red fluorescent 
dye, and Green Fluorescent Protein respectively and viewed under a fluorescence 
microscope to see if there is an association between the two proteins under conditions 
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when PKC is not activated and when PKC is activated. 
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Materials and Methods 
Cell Culture 
PC12 cells were cultured in a 37°C incubator with 10% CO2. The cells were 
maintained in high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 5% BCS, 5% HS, 2mM glutamine, and 102 U/ml penicillin-streptomycin. Cells were 
removed by pipetting media directly onto the growth surface and triturating. 
SK-N-MC cells were cultured in a 37°C incubator with 5% CO2. The cells were 
maintained in DMEM supplemented with 10% FBS, 2mM glutamine, and 102 U/ml 
penicillin-streptomycin. Cells were removed by trypsinating. 
Transfections 
PC12 cells were plated on poly-d-lysine-coated 24-well plates at a density of 2.1 
× 105/well 12-24 h before transfection. SK-N-MC cells were plated on poly-D-lysine 
coated 24 well plates at a density of 1.0 × 105/well 12-24 h before transfection.  
Cells were transiently transfected with Lipofectamine 2000 (Invitrogen). PC12 
cells were transfected with 0.8 μg of total plasmid DNA, containing hDAT vector, GFP 
vector and empty vector, in a concentration of 2:1 lipofectamine to DNA. SK-N-MC cells 
were transfected with 0.3 μg of total plasmid DNA, containing hDAT vector, GFP vector, 
and ShRNA vector. 
PC12 cells were routinely assayed 48 hours post transfection and SKNMC cells 
were routinely assayed 72 hours post transfection. 
Immunocytochemistry and Microscopy 
Transfected PC12 cells were plated on glass cover-slips coated with 1.0 mg/ml 
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poly-D-lysine 48 hours prior to fixation and labeling and transfected SK-N-MC cells 
were plated on glass coverslips coated with 0.2 mg/ml poly-D-lysine 72 hours prior to 
fixation and labeling.  
All cells were rinsed in PBS and fixed in 4% paraformaldehyde prepared in PBS 
for 10 minutes at 25°C. Cells were blocked and permeabilized by incubating in blocking 
solution (PBS, 1% IgG/Protease-free BSA, 5% goat serum, 0.2% Triton-X-100) for 30 
minutes at 25°C, followed by incubation with rat anti-DAT antibody (1:2000 in blocking 
solution) for 1 hour at 25°C. Cells were washed with PBS and incubated with Alexa594-
conjugated goat anti-rat antibody (1:5000 in blocking solution) for 45 minutes at 25°C. 
Cells were washed with PBS, dried and mounted on glass slides with ProLong Gold. 
Cells were visualized with a Zeiss Axiovert 200M microscope using a 63×, 1.4 
N.A. oil-immersion objective, and 0.4-μm optical sections were captured through the z-
axis with a Retiga-1300R cooled CCD camera (Qimaging) using Slidebook 4.0 software 
(Intelligent Imaging Innovations). Z-stacks were deconvolved with a constrained iterative 
algorithm using measured point spread functions for each fluorescent channel using 
Slidebook 4.0 software. All images shown are single 0.4-μm planes through the center of 
each cell. 
Cell Extraction  
Cells were washed with PBS and were lysed with RIPA buffer prepared with 1X 
PMSF and 1X L-P-A. The resulting solution was allowed to shake on a platform in a cold 
room for 20 minutes. The cellular solution was then transferred to µfuge tubes and was 
spun at max speed in a microcentrifuge for 10 minutes in a cold room. A BCA protein 
assay was then performed using BSA standards prepared in RIPA/PIs.  
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SDS-PAGE 
Mini gels were cast with a 12% Acrylamide resolving gel and a 5% Acrylamide 
stacking gel. Prior to loading, samples were allowed to rock at room temperature for 15 
minutes. Samples were loaded, with an equal volume of 2x sample buffer, into the 
stacking gel wells. The sample buffer consisted of 22% Glycerol, 11% 1.0 M Tris, pH 
6.8, 21% H2O, 44% 10%SDS and ΒφBlue. 1X Electrode Running Buffer was added to 
the upper and lower chambers of the gel apparatus and gels were run at 100 V through 
the stacking gel and 200 V through the resolving gel until the dye front reached the 
bottom. The 1X Electrode Running Buffer consisted of 25 mM Tris Base, 192 mM 
Glycine, and 0.1% SDS. 
Western Blot  
After the transfer, the nitrocellulose membrane was removed from the transfer 
apparatus and was blocked in 5% non-fat dried milk in blot wash at room temperature 
shaking on a platform for 45 minutes. The appropriate primary antibodies were prepared 
in blocking solution and were added to the nitrocellulose membrane, which was 
incubated at room temperature shaking on a platform for 1 hour. The antibody was then 
discarded and washed with PBS buffer. The appropriate HRP-conjugated secondary was 
prepared in blocking solution and added to the nitrocellulose membrane, which was 
incubated at room temperature shaking on a platform for 45 minutes. The antibody was 
discarded and then washed with PBS buffer. The blot was then developed using Pierce 
supersignal Dura, 1:2 dilution for 5 minutes and the signal was detected on the 
ChemiDoc system.   
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Results 
 The goal of this project was to determine if 14-3-3-β co-localizes with DAT when 
PKC is un-activated and activated and to see if 14-3-3-β acts within the PKC accelerated 
DAT internalization pathway. In order to accomplish this immunocytochemistry was 
carried out on PC12 cells expressing DAT vector DNA and 14-3-3-βGFP vector DNA 
and immunocytochemistry and shRNA mediated gene silencing were carried out on SK-
N-MC cells expressing DAT vector DNA and endogenous 14-3-3-β. The results were 
visualized by fluorescence microscopy. 
DAT co-localizes with 14-3-3-β at the plasma membrane in PC12 cells 
 In order to see if there was co-localization between 14-3-3-β and DAT, 
immunocytochemistry was carried out on PC12 cells transiently transfected with DAT 
vector DNA and 14-3-3-βGFP vector DNA as described in the materials and methods 
section. The end result was that DAT was specifically tagged with a red fluorescent dye, 
alexa 594. After the immunocytochemistry was performed co-localization was visualized 
with a fluorescent microscope as described in the materials and methods section. PC12 
cells were chosen because they are easily cultured and can endure the experimental 
techniques applied to them.  
 The fluorescent signals in Figure 7A (left) show that DAT is found at the surface 
of the cell and the fluorescent signals in Figure 7A (center) show that 14-3-3-βGFP is 
more dispersed throughout the cell than DAT but still concentrated at the surface of the 
cell. This is easily seen when 14-3-3-βGFP is compared to Figure 7B (center) which 
contains the GFP control. Figure 7A (right) which contains the merge, reveals co-
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localization at the surface as evidenced by the yellow signal. However the co-localization 
does not occur throughout the whole membrane but only in certain areas of the 
membrane.  
DAT does not co-localize with 14-3-3-β  in internal vesicles in PC12 cells  
 In order to see if 14-3-3-β still co-localizes with DAT during PKC accelerated   
DAT internalization, prior to the fixation step in the immunocytochemistry protocol, the 
PC12 cells were treated with PMA to cause DAT to internalize into endosomes.  
 The fluorescent signals in Figure 8A (left) show that DAT is found dispersed 
inside the cell in internal puncta consistent with PMA exposure and internalization into 
endosomes. The fluorescent signals in Figure 8A (center) show that 14-3-3-βGFP is also 
dispersed inside the cell. However, it is not dispersed in the same pattern as DAT. 
Furthermore the fluorescent signals in Figure 8A (right) which contains the merge, 
reveals an absence of any yellow color.  
 Despite the fact that DAT co-localizes with 14-3-3-β prior to activation of PKC 
and does not co-localize with 14-3-3-β when PKC is activated, these results do not 
provide any information on whether or not 14-3-3-β is part of the PKC accelerated DAT 
internalization pathway.  
14-3-3-β  is endogenously expressed in SK-N-MC cells 
 In order to see if 14-3-3-β acts within the PKC accelerated DAT internalization 
pathway a new cell line was chosen that was already shown to have the molecular 
machinery necessary for this particular internalization pathway and could serve as a 
better model for a human neuron cell if further experiments were needed to be done to 
confirm whether or not 14-3-3-β acts within this pathway. The cell line chosen was SK-
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N-MC cells, which are neuroepithelioma cells derived from a metastatic human brain 
tumor.  
 Given that the Melikian Laboratory has already shown that SK-N-MC cells have 
the molecular machinery necessary for PKC accelerated DAT internalization, a western 
blot for endogenous 14-3-3-β could confirm whether or not the protein has a role in this 
pathway.  
 The results from figure 9 lane 1 show that SK-N-MC cells do in fact contain 14-3-
3-β when compared to figure 9 lane 2 which contains the positive control. In this 
particular experiment the positive control contained lysate from HEK 293 T cells that 
have already been shown by the Melikian Laboratory to express 14-3-3-β endogenously.  
14-3-3-β  knockdown by shRNA 
 In order to see if 14-3-3-β acts within the PKC accelerated DAT internalization 
pathway, short hairpin RNAs (shRNAs) were expressed in SK-N-MC cells that targeted 
endogenously produced 14-3-3-β mRNA for degradation. Thus by knocking out the 14-3-
3-β protein, immunostaining DAT with alexa 594 and examining the absence or presence 
of DAT trafficking by fluorescence microscopy it could be determined whether or not 14-
3-3-β acts within the DAT PKC induced endocytosis pathway.   
 However before those experiments were conducted it needed to be shown that the 
shRNAs were effective at knocking down 14-3-3-β. In figure 10 it can be seen that all 
three of the shRNAs used were effective at knocking down 14-3-3-β. Given that 
YWHAB shRNA 7 was the most effective at knocking down 14-3-3-β it was chosen for 
the subsequent knockdown experiment.    
PKC accelerated DAT internalization is likely 14-3-3-β dependent in SK-N-MC cells 
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 In order to see if 14-3-3-β is needed for PKC accelerated DAT internalization in 
SK-N-MC cells, YWHABShRNA7-GFP vector DNA and DAT vector DNA were 
transiently transfected into SK-N-MC cells and immunochemistry and fluorescence 
microscopy were carried out as described in the materials and methods section. 
 In figure 11A, which serves as the positive control, SK-N-MC cells are transiently 
transfected with DAT and GFP vector DNA. In figure 11A (left top row) DAT 
internalization upon exposure to PMA is clearly seen and in figure 11A (left bottom row) 
DAT surface staining upon exposure to Vehicle (-PMA) is clearly seen in accordance 
with past results from the Melikian Laboratory. However when SK-N-MC cells are 
transiently transfected with DAT and YWHABShRNA7-GFP vector DNA, the cells in 
figure 11B (left top row) and figure 11B (left bottom row) clearly show DAT surface 
staining under PMA conditions and Vehicle conditions respectively. Thus it can be 
concluded that 14-3-3-β likely acts within the PKC accelerated DAT internalization 
pathway.  
The reason it is only likely to act within this pathway is because the experiment 
has not been repeated enough times to obtain interpretable results. The reasons for this 
were that SK-N-MC cells were difficult to grow on cover slips used for fluorescence 
microscopy and that the transfection efficiencies using lipofectamine 2000 (Invitrogen) 
were very low.  
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Discussion 
The data compiled in this project shows that 14-3-3-β co-localizes with DAT at 
part of the surface of PC12 cells when PKC is not activated and that it does not co-
localize with DAT in internal vesicles in the cytoplasm of PC12 cells when PKC is 
activated. Furthermore, data suggests that 14-3-3-β is needed for PKC accelerated DAT 
internalization to occur in SK-N-MC cells. However, more knockdown experiments will 
have to be carried out to confirm this.  
Given this data it is impossible to conclude what 14-3-3-β’s exact role is in 
regulated DAT trafficking. Never the less a reasonable hypothesis can be drawn from the 
data. Given that 14-3-3-β has a role in regulated DAT trafficking in a membrane 
associated manner with DAT it is possible that it could be part of an adaptor complex that 
is responsible for recruiting DAT to molecules, such as clathrin, that are responsible for 
creating an endocytic pit from where DAT can internalize. This hypothesis is more 
convincing when one thinks about the breaking model proposed by the Melikian 
Laboratory that was discussed earlier (see figure 5).  
In this model a molecule that acts as a brake is thought to bind DAT at the FREK 
sequence of its carboxy terminus. When this break is bound to DAT, it cannot access the 
endocytic pit from where it can be internalized. Most of the DAT are bound to these 
brakes so most of the DAT cannot access the pit, but some of the DAT are not bound to 
these breaks so some of the DAT can access the pit from where they can be internalized. 
This explains why DAT internalizes under basal conditions. When PKC is activated it is 
thought that the brakes that most of the DAT are bound to are released causing an 
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increase in DAT internalization rates. This explains why increased DAT internalization 
rates are observed experimentally when PKC is activated by PMA.  
In the model proposed by the Melikian Laboratory, the adaptor complex could 
bind to DAT that was bound to a brake. However it is quite possible that the braking 
molecule could make the LAYAI sequence inaccessible to an adaptor complex which 
would still be consistent with experimental observations.  
If one then thinks of this new model then all of the observations made in this 
experiment can be explained. First, the shRNA knockdown experiments resulted in a loss 
of PKC accelerated DAT internalization because the adaptor complex was no longer 
functional and thus could not recruit DAT to an endocytic pit for internalization. 
Secondly, the co-localization of 14-3-3-β with DAT at part of the membrane of PC12 
cells is due to the fact that most of the DAT at the membrane is bound by a braking 
molecule which prevents the binding of an adaptor complex. Thirdly, the absence of co-
localization of 14-3-3-β with DAT in internal vesicles is due to the fact that the adaptor 
complex disassociates from DAT once it is internalized into an endosome. 
In order to test the hypothesis that 14-3-3-β is part of an adaptor complex that 
associates with the LAYAI sequence found at the carboxy terminus of DAT, site-directed 
mutagenesis should be carried out that converts the LAYAI sequence all to Alanines. 
Once this has been achieved the co-localization experiments performed in this project 
should be repeated to see if 14-3-3-β still co-localizes with DAT under conditions when 
PKC is not activated. If DAT does not co-localize with 14-3-3-β under these conditions 
then it can be concluded that 14-3-3-β indirectly associates with the LAYAI sequence 
and is most likely part of an adaptor complex. Future investigations of 14-3-3-β’s role in 
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regulated  DAT trafficking should incorporate these experiments. 
Proper dopamine neurotransmission is critical for the human brain to function. It 
is thought that when this transmission is terminated too early or too late that various 
mental disorders, such as Schizophrenia and ADHD emerge. It is clear that by regulating 
the amount of DAT that is present at the synapse, dopamine neurotransmission can be 
regulated. The results from this project have provided an improved understanding of the 
way by which DAT is regulated, namely that 14-3-3-β is involved in its regulated 
trafficking in a membrane associated manner. Future work may be able to expose 14-3-3-
β’s exact role in DAT regulation, such as it being part of an adaptor complex. If this is 
the case then drugs can be designed to bind to the LAYAI sequence, in order to inhibit 
the binding of adaptor complex and thereby shorten dopamine neurotransmission. These 
drugs could then be used to treat a mental disorder such as Schizophrenia. It is clear that 
by understanding how DAT is regulated by the cell, treatments can emerge for the 
multitude of disorders related to improper dopamine neurotransmission. 
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Figures 
 
 
 
 
 
 
Figure 1: Anatomy of a Neuron 
The neuron consists of dendrites, a cell body, or soma, with a nucleus, and an axon. All three parts function 
to transmit electro-chemical information through the neuron (Cherry). 
 
 
 
 
 
 
Figure 2: Neurotransmission 
Once an action potential is generated it induces vesicles at the terminal axon to release neurotransmitters 
(NT) into the synaptic cleft. Upon release into the synaptic cleft neurotransmitters can bind to receptors on 
the postsynaptic neuron to induce an action potential (“Neurotransmission: Neurologic Disorders: Merck 
Manual Professional”).  
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Figure 3: Receptor-Mediated Endocytosis 
Upon binding of the ligand the receptor is internalized into early endosomes, from where it is either 
recycled back to the plasma membrane or degraded (“The Pathway of Receptor Mediated Endocytosis”).  
 
 
 
 
 
 
 
Figure 4: Structure and Topology of the Dopamine Transporter Protein 
A model of DAT showing the 12 transmembrane segments connected by extracellular and intracellular 
loops with the N and C termini located in the cytosol. (Vaughan et al). 
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Figure 5: DAT Endocytosis Breaking Mechanism 
a) An endocytic adaptor complex is bound to the DAT 591–596 region (LAYAIA), but a braking 
mechanism slows down the rate of DAT internalization in a way that requires the DAT residues 587–590 
(FREK). b) When PKC is activated, the braking mechanism is dissociated, and DAT is able to interact with 
the endocytic machinery, enhancing endocytic rates (Boudanova et al).  
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Figure 6: Crystal Structure Model of 14-3-3ζ 
a) The 14-3-3 dimer. Each monomer contains 9 alpha-helices. b) A surface representation of a 14-3-3ζ 
monomer. The acidic, basic and hydrophobic residues are displayed as red blue and green respectively. c) a 
view of a) rotated 90 degrees so that the bound phosphopeptide is shown. d) The solvent accessible surface 
of 14-3-3ζ. e) Surface representation of 14-3-3ζ with its bound phosphopeptide. (Taken from Fu et al, 
2000) 
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Figure 7: DAT Co-localization with 14-3-3-β 
a) The cell was transfected with DAT vector DNA and 14-3-3-βGFP vector DNA. The merge of the two 
images reveals a yellow color at part of the surface of the cell. b) The cell was transfected with DAT vector 
DNA and GFP vector DNA to serve as the positive control. The merge of the two images reveals no color 
change at the surface of the cell. 
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Figure 8: DAT PKC Mediated Down Regulation 
DAT in both PC12 cells was induced to internalize by PKC activation. a) The cell was transfected with 
DAT vector DNA and 14-3-3-βGFP vector DNA. The merge of the two images reveals no change in color. 
b) The cell was transfected with DAT vector DNA and GFP vector DNA to serve as the positive control. 
The merge of the two images reveals no change in color. 
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Figure 9: 14-3-3-β Expression in SK-N-MC Cells 
Lane 1 contains lysate from SK-N-MC cells and shows a dark band which correspond to 14-3-3-β. Lane 2 
contains lysate from HEK 293 T cells to serve as the positive control.    
 
 
Figure 10: 14-3-3-β Knockdown Experiments 
Protein knockdown experiment showing the effectiveness of each of the three ShRNAs (6, 7 and  8) at 
knocking down 14-3-3-β. Each band corresponding to 14-3-3-β was normalized to actin and then compared 
to the GFP control. The  ** refers to a p<0.01. (Luke Gabriel Melikian Laboratory) 
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Figure 11: shRNA Knockdown of 14-3-3-β in SK-N-MC Cells 
a) Both SK-N-MC cells were transfected with DAT and GFP vector DNA to serve as the control. Upon 
exposure to PMA (top row) DAT is internalized and upon exposure to Vehicle (bottom row) DAT stays at 
the surface. b) Both SK-N-MC cells were transfected with DAT and YWHABshRNA7-GFP vector DNA 
and upon exposure to PMA (top row) and Vehicle (bottom row) DAT stays at the surface.  
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